{"schema_version":"secwatch.filing_event.v1","accession":"0001750284-25-000007","form_type":"8-K","ticker":"OLMA","cik":"0001750284","company_name":"Olema Pharmaceuticals, Inc.","filed_at":"2025-09-02T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.871312+00:00","generated_at":"2026-05-17T08:55:25.511027+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Olema enters clinical trial agreement with Pfizer for palazestrant + atirmociclib phase 1b/2","bullets":["Phase 1b/2 study to evaluate safety and combinability of palazestrant plus Pfizer’s investigational CDK4 inhibitor atirmociclib in ER+/HER2- metastatic breast cancer.","Study planned for approximately 35 patients with initiation anticipated in H2 2025.","Results to inform potential Phase 3 pivotal trial in frontline metastatic setting.","Olema retains full global commercial and marketing rights to palazestrant; Pfizer supplies atirmociclib.","This is Olema’s second clinical trial agreement with Pfizer; prior agreement from Nov 2020 for palazestrant + palbociclib."],"urls":{"canonical":"https://secwatch.observer/filing/0001750284-25-000007","json":"https://secwatch.observer/filing/0001750284-25-000007.json","markdown":"https://secwatch.observer/filing/0001750284-25-000007.md","text":"https://secwatch.observer/filing/0001750284-25-000007.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1750284/000175028425000007/0001750284-25-000007-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1750284/000175028425000007/olma-20250902.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T08:55:25.511027+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}